Anagrelide 13C3
| Chemical Name | Anagrelide 13C3 |
|---|---|
| Alternate Names | Anagrelide Stable Isotopes, Stable Isotopes of Anagrelide |
| CAT No. | CS-O-06409 |
| CAS Registry# | 1219531-58-4 |
| Category | Stable Isotopes |
| Stock | Enquire |
| Mol. Wt. | 259.07 g/mol |
| Mol. For. | C₇¹³C₃H₇Cl₂N₃O |
| Hazardous | This is not a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Anagrelide |
| Smileys | C1C2=C(C=CC(=C2Cl)Cl)N=C3N1CC(=O)N3 |
| Canonical Smiles | C1C2=C(C=CC(=C2Cl)Cl)N=C3N1CC(=O)N3 |
| InchIKey | OTBXOEAOVRKTNQ-PTCNTQLJSA-N |
| Inchl | InChI=1S/C10H7Cl2N3O/c11-6-1-2-7-5(9(6)12)3-15-4-8(16)14-10(15)13-7/h1-2H,3-4H2,(H,13,14,16)/i4+1,8+1,10+1 |
| IUPAC | 6,7-dichloro-3,5-dihydro-1H-(2,4,5-13C3)imidazolo[2,1-b]quinazolin-2-one |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Anagrelide 13C3 is a stable isotope-labeled version of Anagrelide, a medication commonly used for the treatment of essential thrombocythemia, a disease characterized by the overproduction of platelets in the blood. Anagrelide is a selective phosphodiesterase III inhibitor that works by reducing the number of platelets produced in the bone marrow. As a result, it helps prevent blood clots and other complications associated with essential thrombocythemia.
The chemical formula of Anagrelide 13C3 is C10H7N3O, and its molecular weight is 181.19 g/mol. It is a white to off-white powder that is soluble in water, ethanol, and methanol. Anagrelide 13C3 is used in clinical and preclinical studies as a tracer compound to study its pharmacokinetic and pharmacodynamic properties in the body.
Anagrelide 13C3 is typically administered orally in the form of a capsule or tablet, with dosages ranging from 0.5 mg to 2.5 mg per day. The medication is known to have several side effects, including headache, dizziness, nausea, and diarrhea. Patients with liver or kidney problems are advised to use Anagrelide with caution, as the medication may worsen their condition.
In conclusion, Anagrelide 13C3 is a stable isotope-labeled version of Anagrelide used in clinical and preclinical studies to study its pharmacokinetic and pharmacodynamic properties. It works by reducing the number of platelets produced in the bone marrow, and is typically administered orally in the form of a capsule or tablet.
Get an Instant Quote
Related Compounds
Anagrelide 13C2-15N-D2 |